The Trump administration announced deals on Thursday with pharmaceutical giants Novo Nordisk and Eli Lilly that would lower the cost of GLP-1 drugs for many Americans.
Kisqali is already FDA approved, but the new data means it could be used in a broader range of patients.
How much this will impact a nationwide overdose crisis is not clear, even though better access to naloxone is a priority.
The American Academy of Pediatrics said it's a disease with genetic, social and environmental factors.
Fentanyl deaths are rising, especially in Harris County, but researchers say they've found a possible solution to this epidemic.
The ruling could threaten access to sexual and reproductive health care for more than 150 million working Americans who are on employer-sponsored health care plans.